Clinical Trial Update: Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating EXPAREL infiltration into the TAP for C-section pain management vs. bupivacaine alone, with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C-section

Drugs mentioned

• Bupivacaine (Bupivacaine)
• Exparel (liposomal bupivacaine)

Snippet

Sponsor: Pacira Pharmaceuticals, Inc | Conditions: C-Section, Pain Management | Phase 4 | Status: COMPLETED | Results posted: 2021-01-06